Polycystic Ovary Syndrome: A Dive into Diagnosis, Symptoms, and Treatments

Polycystic ovary syndrome affects an estimated 10 to 13 percent of women of reproductive age worldwide, making it the most common endocrine disorder in this population and the leading cause of anovulatory infertility. Yet despite how widespread it is, PCOS remains one of the most under-recognized conditions in women’s health: up to 70 percent of the people who have it are never formally diagnosed, often after years of dismissed symptoms.

What Is PCOS, Really? A Hormonal and Metabolic Condition

PCOS is not one disease with a single cause but a syndrome: a cluster of features that can look quite different from one woman to the next. At its core, it involves some combination of three things: irregular or absent ovulation, elevated androgen hormone levels or their visible signs, and, in some but not all cases, a distinctive pattern of small follicles on the ovaries.

Underlying much of this is insulin resistance. A meaningful proportion of women with PCOS, including many who are not overweight, experience some degree of insulin resistance and its downstream hormonal effects, and the resulting increased risk for glucose abnormalities holds regardless of age or body mass index [4]. When cells resist insulin’s signal, the pancreas compensates by producing more of it, and the resulting higher circulating insulin levels push the ovaries to produce more androgens, reinforcing the hormonal imbalance that defines the condition. This is one reason PCOS is now understood as fundamentally metabolic as much as reproductive, a framing the PMOS name change was specifically designed to capture [2].

How PCOS Is Diagnosed: The Rotterdam Criteria and Four Phenotypes

The internationally recognized diagnostic framework, first established in Rotterdam in 2003 and most recently updated in the 2023 International Evidence-based Guideline, requires that a woman meet at least two of the following three criteria, once other conditions such as thyroid disease, hyperprolactinemia, and congenital adrenal hyperplasia have been ruled out [4]:

• Clinical or biochemical signs of excess androgens, such as hirsutism, persistent acne, or elevated blood testosterone.
• Ovulatory dysfunction. Irregular, infrequent, or absent menstrual periods.
• Polycystic ovarian morphology. Twenty or more follicles in at least one ovary on ultrasound, or an elevated anti-Mullerian hormone (AMH) level as an alternative marker in adults [4].

A nuance the 2023 update made explicit: when irregular cycles and clinical hyperandrogenism are both already present, ultrasound and AMH testing add nothing to the diagnosis and can be skipped. In adolescents, ultrasound and AMH are not recommended at all, since normal pubertal ovaries often look similar; teenagers instead need both hyperandrogenism and ovulatory dysfunction present before a diagnosis is made [4].

Figure 1. Diagnosis requires any two of three Rotterdam criteria, which is why PCOS presents as four distinct phenotypes.

Because the “two of three” rule allows several different combinations of features, clinicians recognize four distinct phenotypes, and they are not equally common or equally severe. A 2025 cohort study measuring insulin resistance across all four found meaningful differences in how much metabolic risk each one carries [10]:

These figures come from a single cohort and should not be read as a fixed rule for every patient, but the pattern they illustrate holds up across the literature: phenotype A tends to carry the heaviest metabolic burden, and phenotype D, lacking the visible hyperandrogenism that often prompts a workup in the first place, is the phenotype most likely to go unrecognized.

Recognizing the Signs: How PCOS Shows Up in the Body

Because PCOS touches the reproductive, metabolic, dermatologic, and psychological systems at once, its presentation rarely fits a single tidy picture. Some women are diagnosed after years of irregular cycles; others after a dermatologist notices persistent hormonal acne; others only after struggling to conceive.

Figure 2. Selected clinical features of PCOS across body systems. Presentation varies widely from person to person.

One sign worth calling out specifically: acanthosis nigricans, the velvety, darkened patches of skin that can appear at the neck, underarms, or groin, is a visible marker of underlying insulin resistance and is often one of the earliest physical clues a clinician notices, even before formal glucose testing [1][4].

The Long-Term Health Stakes of Unmanaged PCOS

PCOS is often framed around fertility, but its longer-term health consequences extend well beyond the reproductive years, which is exactly why ongoing management matters even for women who are not currently trying to conceive.

• Type 2 diabetes. Women with PCOS carry an increased risk of impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes independent of age or BMI; the 2023 guideline recommends screening at diagnosis and reassessment every one to three years [4].
• Cardiovascular disease. Absolute cardiovascular risk before menopause remains low, but the relative risk is elevated enough that all women with PCOS should have a lipid profile at diagnosis and annual blood pressure monitoring [4].
• Non-alcoholic fatty liver disease. A systematic review pooling multiple studies found NAFLD in an estimated 43 percent of women with PCOS, compared with roughly 25 percent in the general population, with insulin resistance and androgen levels as the strongest predictors [9].
• Endometrial cancer. Chronic anovulation leaves the uterine lining unopposed by regular progesterone, markedly raising the relative risk of endometrial hyperplasia and cancer, even though absolute risk stays low; cycle regulation and progestogen therapy are the primary prevention strategies [4].
• Mental health. A synthesis of systematic reviews found pooled depressive-disorder prevalence around 35 percent in women with PCOS, alongside significantly elevated anxiety symptoms, and international guidelines now recommend routine screening for both at diagnosis [7][4].
• Pregnancy complications and sleep apnea. Pregnant women with PCOS face higher rates of gestational diabetes, preeclampsia, and preterm delivery, and PCOS is independently associated with a higher prevalence of obstructive sleep apnea regardless of weight [4].

Evidence-Based Treatment: What Actually Works

There is no cure for PCOS, and treatment is built around managing the specific combination of symptoms a woman has, rather than the syndrome as a single entity. The 2023 International Evidence-based Guideline organizes therapy around three broad goals: cycle and androgen control, metabolic risk reduction, and fertility, when that is the priority [4].

Lifestyle as the Foundation

Healthy eating and regular physical activity are recommended as first-line management for every woman with PCOS, and the evidence base does not favor one specific diet or exercise pattern over another. Benefits on insulin sensitivity, cycle regularity, and mood appear even without significant weight loss, and current guidance explicitly warns clinicians against weight-biased messaging, since PCOS-related metabolic changes can make weight management harder than calorie counting alone would suggest [4].

Medication for Cycle Regulation and Androgen Symptoms

Combined oral contraceptives are first-line therapy for menstrual irregularity and hirsutism, with lower-estrogen formulations (below 30 micrograms of ethinylestradiol) performing as well as higher-dose options. Metformin is recommended for women with a BMI of 25 or above, typically started at a low dose and increased gradually to limit gastrointestinal side effects, with periodic monitoring of vitamin B12. For hirsutism that does not respond to six months of oral contraceptives or cosmetic treatment, spironolactone (25 to 100 mg daily) is the preferred second-line anti-androgen given its more favorable safety profile; cyproterone acetate at doses of 10 mg or higher is no longer advised because of an associated meningioma risk [4].

Where Inositol and Other Nutraceuticals Fit

Myo-inositol and D-chiro-inositol are among the most widely marketed nutraceuticals for PCOS, and the evidence deserves an honest look. A systematic review and meta-analysis of 30 randomized trials (2,230 participants), conducted specifically to inform the 2023 guideline update, found some potential metabolic benefit and possible improvement in ovulation with D-chiro-inositol, but concluded the overall evidence remains “limited and inconclusive,” with metformin outperforming inositol on waist-hip ratio and hirsutism and no meaningful difference in reproductive outcomes [5]. Inositol did cause fewer gastrointestinal side effects than metformin, which is a genuine advantage for tolerability, but current guidelines stop short of recommending a specific type or dose, and instead frame it as a shared decision between patient and clinician that weighs this uncertainty against personal preference [4][5]. That evidence-graded honesty, not overstated claims, is what should guide how any inositol-based formulation is positioned to healthcare partners.

An Emerging Option: GLP-1 Receptor Agonists

For women with PCOS and overweight or obesity, GLP-1 receptor agonists (including liraglutide, exenatide, and semaglutide) are an active area of research. A 2025 meta-analysis of 13 randomized trials found GLP-1 therapy reduced body weight by an average of 3.57 kg and BMI by 1.59 kg/m² compared with control groups, alongside meaningful reductions in fasting insulin and insulin resistance scores. Gastrointestinal side effects were common, with roughly three-fold higher odds of nausea and five-fold higher odds of dizziness, and the analysis did not find that GLP-1 therapy meaningfully changed androgen levels compared with metformin or placebo, nor did it report on menstrual regularity as an outcome [6]. In short, this class shows real promise for the metabolic side of PCOS, but the evidence on reproductive and hormonal endpoints is still developing.

Fertility and Family Planning With PCOS

PCOS is the leading cause of anovulatory infertility, but it is also one of the most treatable. For women whose only fertility barrier is anovulation, letrozole is now the recommended first-line ovulation-induction agent, a position reinforced by a 2025 meta-analysis of 32 randomized trials spanning nearly 4,900 women: compared with clomiphene citrate, letrozole produced an 18 percent higher ovulation rate, a 57 percent higher pregnancy rate, and a 54 percent higher live birth rate, while also lowering the risk of multiple pregnancy [8].

When letrozole alone is not enough, second-line options include clomiphene citrate with or without metformin, gonadotrophins, or laparoscopic ovarian surgery, and in vitro fertilization remains a well-established third-line pathway when other approaches have not succeeded [4]. Because PCOS-related metabolic and hormonal factors can also affect pregnancy once conception happens, most guidelines now recommend counseling women early on realistic timelines and the elevated risk of pregnancy complications discussed above, rather than treating fertility and long-term metabolic health as separate conversations.

PCOS is not the only Contramev-line topic where nutraceutical claims have outpaced the underlying evidence. Mevian’s guide to pelvic pain, alpha lipoic acid, and magnesium walks through a closely related case: two supplements marketed for a women’s health condition on the strength of mechanistic, rather than clinical, evidence.

Conclusion

PCOS is common, frequently under-diagnosed, and considerably more than a fertility issue. It is a lifelong metabolic and endocrine condition that touches the skin, the mind, the heart, and the liver, as well as the reproductive system, and the terminology shift to PMOS reflects exactly that broader understanding. What has not changed is the shape of good care: an accurate diagnosis grounded in the Rotterdam criteria, a treatment plan matched honestly to the evidence behind each option, from first-line lifestyle changes and letrozole through to the still-developing case for inositol and GLP-1 therapy, and ongoing attention to the cardiometabolic and mental health risks that persist long after any fertility goals are met.